This is an automatically translated article.
Lung cancer is currently the most common cancer in the world, with 1,825,000 new cases diagnosed in recent years, accounting for 13% of all cancers. Therefore, screening for lung cancer with the annual Cyfra 21-1 quantitative test is essential.1. Who should do the Cyfra 21-1 test?
Quantification of Cyfra 21-1 is a cancer marker commonly found in blood. This quantification is used to aid in the diagnosis and monitoring of lung cancer treatment. This quantification may be increased in some other benign lung diseases.
Quantitative testing of Cyfra 21-1 should be done with the following subjects:
People with suspected lung cancer, tumors or abnormal lesions in the lungs. People with chronic lung disease. The patient is being monitored and treated for non-small cell lung cancer. People working in hazardous and dusty environments. Smokers, pipe tobacco; history of smoking, pipe tobacco. The patient is being monitored for cancers of the esophagus, breast, pancreas, cervix or bladder as a second marker for follow-up.
Người có bệnh lý mãn tính ở phối nên được thực hiện xét nghiệm Cyfra 21-1
2. How is the Cyfra 21-1 test used to diagnose lung cancer?
In patients with lung cancer, Cyfra 21-1 quantification was higher than 3.5 ng/mL, with a sensitivity of 43% and a specificity of 89%. Cyfra 21-1 usually decreases after surgery or chemotherapy and may increase again when the cancer recurs. Specifically, the Cyfra 21-1 index for each type of lung cancer is as follows:
In the diagnosis of primary lung cancer in general: Cyfra 21-1 with a cutoff value of 3.5 ng/mL has a sensitivity of 43% and The specificity was 89%. In the diagnosis of non-small cell lung cancer: Cyfra 21-1 has a sensitivity of 59% to 78% and a specificity of 94%. The degree of plasma Cyfra 21-1 elevation was proportional to the extent of tumor invasion (T1: 15%, T2: 49%, T3: 68%, T4: 55%) and cancer stage (I: 29%) , II: 56%, III: 63%, IV: 63%). In small cell lung cancer: Cyfra 21-1 sensitivity is 19% and specificity is 94%. In small cell lung cancer, the first tumor marker selected was NSE with a sensitivity of 54%, however, when combined with Cyfra 21-1, the clinical sensitivity of NSE increased to 62%. In squamous cell lung cancer: Cyfra 21-1 has a diagnostic value (+) of 84.6%, while SCC and CEA only have a diagnostic value (+) of 30 and 20%, respectively. In adenocarcinoma and large cell lung cancer: Cyfra 21-1 is a marker of adenocarcinoma with a sensitivity of 74.3% and of large cell lung cancer with a sensitivity of 75. ,3%. The sensitivity of this cancer marker is increased by about 10% when combined with CEA. If both of these cancer markers are positive (+), then to track the progression of these cancers over time, just one cancer marker is enough. Cyfra 21-1 is a potent pre-treatment independent predictor of lung cancer in both non-metastatic and metastatic adenocarcinoma.
Bệnh viện Đa khoa Quốc tế Vinmec Hạ Long là địa chỉ tin cậy trong khám chữa bệnh
Cyfra 21-1 helps to support the diagnosis of non-small cell lung cancer, this test is often indicated in patients who have been and are being treated for small cell lung cancer to help support in monitoring response assessment treatment.
However, the slight increase in the indicators is not entirely due to cancer. There are some other causes that increase Cyfra 21-1 other such as chronic bronchitis, chronic lung disease (COPD), smoking, water pipe,... In case the patient has clinical symptoms that are suspected of cancer Lung cancer and a Cyfra 21-1 test >30 ng/mL is suggestive of non-small cell lung cancer and requires further testing.
Vinmec Ha Long International General Hospital is one of the trusted addresses that many customers trust to come for medical examination and treatment. At the hospital that provides this quantitative testing service with a team of leading medical doctors and doctors in the province specializing in Biochemistry, dedicated and responsible; using Cobas E automatic immunoassay for the most accurate results and successfully supporting the treatment of lung cancer and other cancers for patients.
Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.
